aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
aTyr Pharma (Nasdaq: LIFE) announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The poster, titled 'ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway,' will focus on its potential to sensitize aggressive and chemoresistant TNBC subtypes to chemotherapy. ATYR2810 is in IND-enabling studies aimed at targeting NRP2, associated with poor outcomes in various cancers, suggesting significant therapeutic potential.
- Presentation at a prominent conference may enhance visibility and credibility in the oncology space.
- ATYR2810 shows promise as a potential treatment for aggressive tumors linked to NRP2, which is associated with poor cancer outcomes.
- None.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually.
Details of the poster presentation are as follows:
Title: ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizes highly aggressive and chemoresistant TNBC subtypes to chemotherapy
Authors: Zhiwen Xu, Alison Barber, Christoph Burkart, Hira Lal Goel, Justin Rahman, Kristina Hamel, Zachary Fogassy, Lisa Eide, Clara Polizzi, Jasmine Stamps, Sofia Klopp Savino, Luke Burman, Esther Chong, Suzanne Paz, Arthur M. Mercurio, Leslie A. Nangle. aTyr Pharma, University of Massachusetts Chan Medical School.
Abstract Control Number: 7998
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry
Session Date and Time: Monday, April 11, 2022 from 1:30PM – 5:00PM ET
Location: New Orleans Convention Center, Exhibit Halls D – H, Poster Section 16
Poster Board Number: 10
Permanent Abstract Number: LB085
About ATYR2810
aTyr is developing ATYR2810 as a potential therapeutic for certain aggressive tumors where neuropilin-2 (NRP2) is implicated. ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF. ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr’s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways. NRP2 is a cell surface receptor that is highly expressed in certain tumors, in the lymphatic system and on key immune cells implicated in cancer progression. Increased NRP2 expression is associated with worse outcomes in many cancers. Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors. ATYR2810 is currently undergoing IND-enabling studies.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of NRP2 antibodies, including ATYR2810; timelines and plans with respect to certain development activities; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
| Contact: | |
| Ashlee Dunston | |
| Director, Investor Relations and Corporate Communications | |
| adunston@atyrpharma.com |
FAQ
What is the upcoming event for aTyr Pharma related to stock symbol LIFE?
What is the focus of aTyr Pharma's presentation at AACR 2022?
What is the therapeutic potential of ATYR2810 according to the press release?
When and where is the poster presentation for ATYR2810 scheduled?
